- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07939490
JULÄINE™ - Neck Skin Laxity Clinical Investigation
A Prospective, Multi-Centre, Single-Arm, Open-Label Pivotal Clinical Investigation to Evaluate the Safety and Clinical Performance of JULÄINE™ in Adults With Neck Skin Laxity
This study will assess the safety of JULÄINE™, an injectable filler containing poly-L-lactic acid (PLLA), and whether it can improve loose skin on the neck.
The main question is whether more than 60% of treated participants show an improvement of at least one level on a neck skin laxity scale, 26 weeks after their final treatment. Improvement will be measured by comparing neck skin looseness before and after treatment.
The study plans to enroll adults aged 18 years or older with mild to moderately severe loose neck skin at three sites. All participants will receive the filler during three treatment sessions, approximately four weeks apart.
Participation will last approximately 14 months, including screening, treatment, and follow-up until 52 weeks after the final treatment. Investigators will assess changes using standardised photographs, measurements of skin elasticity, and questionnaires about participants' views of their neck appearance. The study will also monitor adverse events through the final follow-up visit.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Karina Caramico
- Numéro de téléphone: (+46) 76 336 39 48
- E-mail: k.caramico@nordbergmedical.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults aged 18 years or older with mild to moderate-to-severe neck skin laxity (Grade 2-4 on Neck Laxity Scale).
- Willing to avoid aesthetic procedures involving the neck and lower face and changes to treatments affecting skin quality during the study.
- If of childbearing potential, a negative pregnancy test and agreement to use highly effective contraception throughout treatment and for eight weeks afterward.
- Able to provide written informed consent and comply with study visits, assessments, and post-treatment instructions.
Exclusion Criteria:
- Pregnancy, breastfeeding, or planned pregnancy or reproductive donation/retrieval procedures during the study or within eight weeks after the final visit.
- Previous neck surgery or major maxillofacial/cervical surgery; neck injections within 12 months; neck resurfacing or other aesthetic procedures within six months; or planned procedures during the study.
- Significant neck skin disease, infection, scarring, pigmentation abnormalities, or other conditions interfering with treatment or assessment.
- Prominent neck muscle bands, excessive facial or neck fat, or anatomy unsuitable for injectable treatment, as assessed by the investigator.
- Significant thyroid enlargement, uncontrolled thyroid disease, or other unstable endocrine disease.
- Allergy to device components, coagulation disorders, or anticoagulant/antiplatelet treatment, subject to protocol-defined exceptions.
- Recent immune-modifying treatment, chemotherapy, or systemic corticosteroids above 10 mg prednisone-equivalent daily; relevant corticosteroid/retinoid use; or treatments affecting collagen production.
- Hormone replacement therapy or thyroid medication that does not meet protocol-defined stability requirements.
- Immune deficiency, autoimmune disease, impaired wound healing, or significant malignant, dermatological, or systemic disease.
- Significant recent or expected weight changes, recent bariatric surgery, ongoing postoperative weight loss, or active weight-loss treatment, subject to protocol-defined exceptions.
- Any condition preventing valid informed consent or compliance with study requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: JULÄINE™
|
JULÄINE™, a poly-L-lactic acid (PLLA)-based injectable filler, administered beneath the skin on both sides of the neck during three treatment sessions, approximately four weeks apart. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants With Improved Neck Skin Laxity
Délai: Baseline and 26 weeks after the final treatment session
|
Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement. |
Baseline and 26 weeks after the final treatment session
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants With Improved Neck Skin Laxity at 12 and 52 Weeks
Délai: Baseline and 12 and 52 weeks after the final treatment session
|
Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement. |
Baseline and 12 and 52 weeks after the final treatment session
|
|
Percentage of Participants With Improved Neck Skin Elasticity
Délai: Baseline and 26 weeks after the final treatment session
|
Percentage of participants showing an increase of at least 10% from baseline in the Cutometer R2 parameter, a measure of overall skin elasticity. Higher R2 values indicate greater elasticity. |
Baseline and 26 weeks after the final treatment session
|
|
Investigator-Rated Change in Neck Appearance
Délai: 12, 26, and 52 weeks after the final treatment session
|
Distribution of investigator ratings on the seven-point Global Aesthetic Improvement Scale, ranging from "very much improved" to "very much worse," based on comparisons of standardised post-treatment and baseline photographs. |
12, 26, and 52 weeks after the final treatment session
|
|
Change From Baseline in FACE-Q Appraisal of the Neck Score
Délai: Baseline and 12, 26, and 52 weeks after the final treatment session.
|
Change from baseline in participants' assessment of their neck appearance using the FACE-Q Appraisal of the Neck questionnaire. Raw scores are converted to a score ranging from 0 to 100 using the instrument's scoring algorithm. |
Baseline and 12, 26, and 52 weeks after the final treatment session.
|
|
Change From Baseline in Neck Skin Firmness and Elasticity Measured by Cutometer
Délai: Baseline and 12, 26, and 52 weeks after the final treatment session.
|
Change from baseline in four Cutometer parameters: R0 (skin firmness), R2 (gross elasticity), R5 (net elasticity), and R7 (biological elasticity). Lower R0 values indicate firmer skin, while higher R2, R5, and R7 values indicate greater elasticity. |
Baseline and 12, 26, and 52 weeks after the final treatment session.
|
|
Incidence of Adverse Events and Device Deficiencies
Délai: From the first treatment through 52 weeks after the final treatment session
|
Number and percentage of participants experiencing adverse events, including device-related events, serious events, and unanticipated serious device-related events. Events will be characterised by type, severity, seriousness, and relationship to the device or injection procedure. Device deficiencies will be summarised separately. |
From the first treatment through 52 weeks after the final treatment session
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NB 15-TF-EU-100-38F
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .